Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto® Chew (25 mg/kg fluralaner) or Simparica TRIO® (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)

Reif, Kathryn E.; Bickmeier, Naemi P.; Herrin, Brian H.; Dryden, Michael W.; Normile, Dorothy M.; Jesudoss Chelladurai, Jeba R. J.; Miller, Kamilyah R.; Flowers, Macy R.; Kang, Qing

doi:10.1186/s13071-023-05946-3

Table 2 Efficacy of Bravecto^® and Simparica TRIO^® to control adult Ixodes scapularis infestation upon treatment (Day 0) and at 21 and 28 days post-treatment

From: Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto^® Chew (25 mg/kg fluralaner) or Simparica TRIO^® (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)

			Model ln(count + 1)					Model count directly
				Compared to untreated control		Compared to Simparica TRIO^®			Compared to untreated control		Compared to Simparica TRIO^®
Infestation day¹	Tick count time²	Treatment	Geometric mean ± SE	Test statistic (DOF) P value	Efficacy (%)³	Test statistic (DOF) P value	Efficacy (%)³	Arithmetic mean ± SE	Test statistic (DOF) P value	Efficacy (%)³	Test statistic (DOF) P value	Efficacy (%)³
Day -2 (48 h prior to treatment)	4 h	Untreated control	23.3 ± 2.1					24.0 ± 2.3
		Bravecto^®	25.5 ± 2.4	0.7(13.8) 0.495	0	− 0.2(13.3) 0.822	3.2	26.3 ± 2.2	0.7(14.0) 0.497	0	− 0.3(13.3) 0.759	4.1
		Simparica TRIO^®	26.4 ± 2.8	0.9(13.4) 0.392	0			27.4 ± 2.8	0.9(13.5) 0.371	0
	8 h	Untreated control	19.2 ± 2.3					20.2 ± 2.2
		Bravecto^®	11.9 ± 1.7	− 4.1(7.4) 0.004	38.0	0.1(8.3) 0.951	0	12.6 ± 2.0	− 3.8(5.9) 0.009	37.7	− 0.5(7.9) 0.620	12.2
		Simparica TRIO^®	11.7 ± 3.1	− 2.0(5.9) 0.096	39.0			14.4 ± 3.5	− 1.7(8.0) 0.138	29.0
	12 h	Untreated control	26.5 ± 2.3					27.3 ± 2.5
		Bravecto^®	0.1 ± 0.1	− 63(7.2) < 0.001	99.7	− 2.3(7.0) 0.056	95.1	0.1 ± 0.2	− 11(7.0) < 0.001	99.5	− 1.7(7.0) 0.138	97.8
		Simparica TRIO^®	1.8 ± 1.2	− 5.4(6.8) 0.001	93.0			5.7 ± 3.4	− 5.1(12.9) < 0.001	78.9
	24 h	Untreated control	27.8 ± 2.1					28.4 ± 2.2
		Bravecto^®	− 0.0 ± 0.0	− 47(7.2) < 0.001	100	− 1.0(7.0) 0.351	100	0.0 ± 0.2	− 13(7.0) < 0.001	100	− 1.0(8.5) 0.366	100
		Simparica TRIO^®	0.1 ± 0.2	− 21(10.4) < 0.001	99.5			0.3 ± 0.3	− 13(7.1) < 0.001	99.1
Day 21 (21 days post-treatment)	4 h	Untreated control	14.0 ± 2.6					15.4 ± 2.2
		Bravecto^®	15.8 ± 2.7	0.5(10.4) 0.616	0	− 0.8(8.1) 0.422	14.0	17.4 ± 2.6	0.6(10.0) 0.530	0	− 0.6(7.9) 0.590	7.9
		Simparica TRIO^®	18.4 ± 1.8	1.4(8.0) 0.186	0			18.9 ± 1.5	1.6(8.2) 0.146	0
	8 h	Untreated control	17.0 ± 2.6					18.1 ± 2.1
		Bravecto^®	4.4 ± 1.5	− 3.8(10.3) 0.003	74.0	− 4.4(8.0) 0.002	76.5	6.1 ± 2.0	− 4.2(13.9) < 0.001	66.2	− 5.2(13.3) < 0.001	68.2
		Simparica TRIO^®	18.8 ± 1.5	0.6(10.5) 0.573	0			19.2 ± 1.6	0.4(13.1) 0.670	0
	12 h	Untreated control	23.3 ± 2.9					24.4 ± 2.5
		Bravecto^®	0.2 ± 0.1	− 23(8.5) < 0.001	99.2	− 12(7.5) < 0.001	98.7	0.2 ± 0.2	− 9.7(7.0) < 0.001	99.0	− 5.6(7.0) < 0.001	98.5
		Simparica TRIO^®	14.1 ± 3.1	− 2.2(8.9) 0.055	39.4			16.4 ± 2.9	− 2.1(13.7) 0.056	32.8
	24 h	Untreated control	25.7 ± 2.6					26.5 ± 2.5
		Bravecto^®	0.0 ± 0.0	− 34(7.1) < 0.001	100	− 1.8(7.0) 0.107	100	− 0.0 ± 0.2	− 11(7.0) < 0.001	100	− 1.6(7.2) 0.157	100
		Simparica TRIO^®	0.6 ± 0.4	− 11(9.1) < 0.001	97.8			1.0 ± 0.6	− 10(7.9) < 0.001	96.2
Day 28 (28 days post-treatment)	4 h	Untreated control	15.0 ± 2.4					16.1 ± 2.2
		Bravecto^®	12.2 ± 1.6	− 1.0(5.3) 0.359	18.4	− 0.9(11.4) 0.376	19.6	12.9 ± 1.6	− 1.2(5.7) 0.271	20.2	− 1.2(10.1) 0.251	24.8
		Simparica TRIO^®	15.2 ± 3.0	0.1(11.2) 0.954	0			17.1 ± 3.1	0.3(11.0) 0.797	0
	8 h	Untreated control	18.1 ± 2.0					18.8 ± 1.8
		Bravecto^®	1.4 ± 0.6	− 7.3(9.1) < 0.001	92.2	− 7.1(10.5) < 0.001	92.5	2.1 ± 0.9	− 8.3(10.5) < 0.001	88.7	− 6.7(8.9) < 0.001	89.4
		Simparica TRIO^®	18.9 ± 2.8	0.2(12.9) 0.814	0			20.1 ± 2.5	0.4(12.6) 0.662	0
	12 h	Untreated control	23.9 ± 2.5					24.8 ± 2.2
		Bravecto^®	0.1 ± 0.1	− 29(9.3) < 0.001	99.6	− 17(7.9) < 0.001	99.5	0.1 ± 0.2	− 11(7.0) < 0.001	99.5	− 6.0(7.0) < 0.001	99.4
		Simparica TRIO^®	17.3 ± 3.0	− 1.8(4.1) 0.138	27.7			19.3 ± 3.2	− 1.4(12.5) 0.179	22.2
	24 h	Untreated control	27.9 ± 2.2					28.5 ± 2.2
		Bravecto^®	− 0.0 ± 0.0	− 45(7.2) < 0.001	100	− 2.4(7.0) 0.050	100	− 0.0 ± 0.2	− 13(7.0) < 0.001	100	− 2.0(7.1) 0.083	100
		Simparica TRIO^®	1.0 ± 0.6	− 9.2(8.0) < 0.001	96.6			1.6 ± 0.8	− 11(8.8) < 0.001	94.3

¹Infestaton day relative to treatment day (Day 0)
²Tick count time post-treatment (Day 0) or post-reinfestation (Day 21 or 28)
³Any caculated negative efficacy values are reported as 0

Back to article page

ISSN: 1756-3305

Contact us

Submission enquiries: journalsubmissions@springernature.com

Parasites & Vectors

Contact us